Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon Hospital Health Management Center Study 7 (TOPICS 7).

Heianza Y, Arase Y, Fujihara K, Hsieh SD, Saito K, Tsuji H, Kodama S, Yahagi N, Shimano H, Yamada N, Hara S, Sone H.

Diabetes Care. 2012 May;35(5):1050-2. doi: 10.2337/dc11-1793. Epub 2012 Mar 28.

2.

Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4).

Heianza Y, Arase Y, Fujihara K, Tsuji H, Saito K, Hsieh SD, Kodama S, Shimano H, Yamada N, Hara S, Sone H.

Diabet Med. 2012 Sep;29(9):e279-85. doi: 10.1111/j.1464-5491.2012.03686.x.

PMID:
22510023
3.

Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon Hospital Health Management Center Study 6 (TOPICS 6).

Heianza Y, Arase Y, Hsieh SD, Saito K, Tsuji H, Kodama S, Tanaka S, Ohashi Y, Shimano H, Yamada N, Hara S, Sone H.

Diabetologia. 2012 Dec;55(12):3213-23. doi: 10.1007/s00125-012-2712-0. Epub 2012 Sep 7.

PMID:
22955996
4.

Effect of HbA1c combined FPG on screening diabetes in health check-up.

Li LJ, Zhou JX, Chen HT, Song YL, Xue YM.

Asian Pac J Trop Med. 2012 Jun;5(6):472-5. doi: 10.1016/S1995-7645(12)60081-9.

5.

HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study.

Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, Kodama S, Hsieh SD, Mori Y, Shimano H, Yamada N, Kosaka K, Sone H.

Lancet. 2011 Jul 9;378(9786):147-55. doi: 10.1016/S0140-6736(11)60472-8. Epub 2011 Jun 24.

PMID:
21705064
6.

Fasting plasma glucose and HbA1c as risk factors for Type 2 diabetes.

Inoue K, Matsumoto M, Akimoto K.

Diabet Med. 2008 Oct;25(10):1157-63. doi: 10.1111/j.1464-5491.2008.02572.x.

PMID:
19046193
7.

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group.

Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x.

PMID:
19515182
8.

Cut-off values of fasting and post-load plasma glucose and HbA1c for predicting Type 2 diabetes in community-dwelling Japanese subjects: the Hisayama Study.

Mukai N, Doi Y, Ninomiya T, Hata J, Hirakawa Y, Fukuhara M, Iwase M, Kiyohara Y.

Diabet Med. 2012 Jan;29(1):99-106. doi: 10.1111/j.1464-5491.2011.03378.x.

PMID:
21726278
9.

Recent population changes in HbA(1c) and fasting insulin concentrations among US adults with preserved glucose homeostasis.

Cheng YJ, Kahn HS, Gregg EW, Imperatore G, Geiss LS.

Diabetologia. 2010 Sep;53(9):1890-3. doi: 10.1007/s00125-010-1800-2. Epub 2010 May 27.

PMID:
20517591
10.

High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon Hospital Health Management Center Study 8 (TOPICS 8).

Heianza Y, Arase Y, Fujihara K, Tsuji H, Saito K, Hsieh SD, Kodama S, Shimano H, Yamada N, Hara S, Sone H.

Diabet Med. 2012 Oct;29(10):1285-90. doi: 10.1111/j.1464-5491.2012.03667.x.

PMID:
22486679
11.

Low lung function and risk of type 2 diabetes in Japanese men: the Toranomon Hospital Health Management Center Study 9 (TOPICS 9).

Heianza Y, Arase Y, Tsuji H, Saito K, Amakawa K, Hsieh SD, Kodama S, Shimano H, Yamada N, Hara S, Sone H.

Mayo Clin Proc. 2012 Sep;87(9):853-61. doi: 10.1016/j.mayocp.2012.04.016.

12.

Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.

Karl D, Zhou R, Vlajnic A, Riddle M.

Diabet Med. 2012 Jul;29(7):933-6. doi: 10.1111/j.1464-5491.2012.03640.x.

13.
14.

A retrospective analysis of the fasting plasma glucose and glycosylated hemoglobin and pharmacotherapy change patterns among type 2 diabetes mellitus patients.

Davidson J, Koro C, Arondekar B, Lee BH, Fedder D.

Clin Ther. 2008 Feb;30(2):287-93. doi: 10.1016/j.clinthera.2008.02.007.

PMID:
18343267
15.

Haemoglobin A1c cut-off point to identify a high risk group of future diabetes: results from the Omiya MA Cohort Study.

Kato M, Noda M, Suga H, Nakamura T, Matsumoto M, Kanazawa Y; Omiya MA Cohort Study Group.

Diabet Med. 2012 Jul;29(7):905-10. doi: 10.1111/j.1464-5491.2012.03572.x.

16.

Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies.

Soulimane S, Simon D, Shaw JE, Zimmet PZ, Vol S, Vistisen D, Magliano DJ, Borch-Johnsen K, Balkau B.

Diabet Med. 2011 Nov;28(11):1311-8. doi: 10.1111/j.1464-5491.2011.03403.x.

18.

Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening.

Schöttker B, Raum E, Rothenbacher D, Müller H, Brenner H.

Eur J Epidemiol. 2011 Oct;26(10):779-87. doi: 10.1007/s10654-011-9619-9. Epub 2011 Sep 27.

PMID:
21947790
19.

Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study.

Wang W, Lee ET, Howard BV, Fabsitz RR, Devereux RB, Welty TK.

Diabetes Care. 2011 Feb;34(2):363-8. doi: 10.2337/dc10-1680.

20.

HbA(1c) in adults without known diabetes from southern Europe. Impact of the new diagnostic criteria in clinical practice.

Bernal-Lopez MR, Santamaría-Fernandez S, Lopez-Carmona D, Tinahones FJ, Mancera-Romero J, Peña-Jimenez D, Jansen-Chaparro S, Baca-Osorio AJ, Cuesta-Muñoz AL, Serrano-Rios M, Gomez-Huelgas R.

Diabet Med. 2011 Nov;28(11):1319-22. doi: 10.1111/j.1464-5491.2011.03317.x. Epub 2011 Apr 16.

PMID:
21966956

Supplemental Content

Support Center